There is one answer in each file.  copilot_answer_adaptive_design.md  is the stronger overall answer, but neither is fully authoritative or complete.

┌──────────────┬───────────────────────────────────────┬────────────────────────────────────┐
│ Criterion    │ copilot_answer_adaptive_design.md     │ adaptive_trial_design.md           │
├──────────────┼───────────────────────────────────────┼────────────────────────────────────┤
│ Truthfulness │ Mostly accurate, but occasionally     │ More cautious and transparent, but │
│              │ overstates FDA “support” and blurs    │ relies heavily on secondary        │
│              │ guidance, drafts, and initiatives     │ sources and admits key claims were │
│              │                                       │ unverified                         │
├──────────────┼───────────────────────────────────────┼────────────────────────────────────┤
│ Robustness   │ Strong synthesis of statistical,      │ Weak synthesis; emphasizes         │
│              │ operational, and oncology-specific    │ document metadata and research     │
│              │ considerations                        │ limitations                        │
├──────────────┼───────────────────────────────────────┼────────────────────────────────────┤
│ Completeness │ Covers adaptation types, error        │ Omits much of the substantive      │
│              │ control, integrity, estimation,       │ guidance and several important     │
│              │ simulation, oncology applications,    │ current documents                  │
│              │ and FDA engagement                    │                                    │
├──────────────┼───────────────────────────────────────┼────────────────────────────────────┤
│ Usefulness   │ Direct, organized, actionable         │ Cumbersome and dominated by        │
│              │                                       │ provenance/confidence commentary   │
└──────────────┴───────────────────────────────────────┴────────────────────────────────────┘

 copilot_answer_adaptive_design.md 

Strengths: It accurately captures the main 2019 FDA principles: prospective planning, Type I error control, protection of interim information, reliable estimation, simulation of operating characteristics, and early FDA consultation. It also explains relevant oncology uses—dose selection, enrichment, seamless trials, and master protocols—in a clear, practical structure.

Weaknesses: It provides no citations or exact guidance statuses. It should distinguish binding regulations from nonbinding guidance, final guidance from drafts, and formal guidance from initiatives. “FDA supports” or is “particularly supportive” is stronger than the more defensible formulation that FDA is receptive when validity and trial integrity are demonstrated. It also omits the important August 2024 final oncology dosage-optimization guidance, while treating Project Optimus as part of the guidance framework. The Bayesian guidance should be identified as the January 2026 draft, and ICH E20 as a draft rather than settled policy.

 adaptive_trial_design.md 

Strengths: It identifies the central 2019 guidance, the 2022 oncology master-protocol and expansion-cohort guidances, and the June 2026 broader master-protocol draft. Its explicit uncertainty is intellectually honest.

Weaknesses: It does not adequately answer “summarize FDA guidance.” It spends excessive space on dockets, Federal Register notices, secondary-source provenance, harness confidence scores, and research limitations. It openly states that the principal guidance was not fully reviewed. Core subjects—adaptation types, multiplicity, operational bias, estimation, simulations, enrichment, and practical oncology implications—are missing or only briefly mentioned. It also omits the 2024 oncology dosage guidance, ICH E20, the January 2026 Bayesian draft, Project Optimus, and meaningful discussion of CID engagement. The 2019 guidance itself is dated November 2019, although its availability notice appeared December 2.

Verdict:  copilot_answer_adaptive_design.md  is substantially more robust and complete and therefore the better solution overall.  adaptive_trial_design.md  is more transparent about evidentiary limitations, but that transparency does not compensate for its incomplete and weakly synthesized answer. The ideal response would retain the first answer’s structure while adding primary FDA citations, exact final/draft statuses, the 2024 oncology dosage guidance, and more qualified regulatory language.

Ok the scores are metadata in adaptive_trial_design produced by the harness parsec. Ignoring those, re-run your assessment

Ignoring everything after the  ---  delimiter, the result is closer but unchanged:  copilot_answer_adaptive_design.md  remains the better overall answer.

┌──────────────┬───────────────────────────────────┬────────────────────────────────────────┐
│ Criterion    │ Better answer                     │ Reason                                 │
├──────────────┼───────────────────────────────────┼────────────────────────────────────────┤
│ Truthfulness │ adaptive_trial_design.md narrowly │ More carefully distinguishes final     │
│              │                                   │ guidance, drafts, and secondary        │
│              │                                   │ evidence; avoids broad claims of FDA   │
│              │                                   │ “support.”                             │
├──────────────┼───────────────────────────────────┼────────────────────────────────────────┤
│ Robustness   │ copilot_answer_adaptive_design.md │ Explains statistical validity,         │
│              │                                   │ operational bias, estimation,          │
│              │                                   │ simulations, and regulatory engagement │
│              │                                   │ coherently.                            │
├──────────────┼───────────────────────────────────┼────────────────────────────────────────┤
│ Completeness │ copilot_answer_adaptive_design.md │ Covers substantially more adaptive     │
│              │                                   │ methods and oncology applications.     │
├──────────────┼───────────────────────────────────┼────────────────────────────────────────┤
│ Directness   │ copilot_answer_adaptive_design.md │ Actually synthesizes the guidance      │
│              │                                   │ rather than mainly cataloguing         │
│              │                                   │ documents.                             │
└──────────────┴───────────────────────────────────┴────────────────────────────────────────┘

The Parseс answer’s substantive weaknesses remain: it explicitly was not based on a full reading of the central guidance, offers little detail on adaptation methods, and omits important developments such as the August 2024 oncology dosage-optimization guidance, ICH E20, the January 2026 Bayesian draft, Project Optimus, and CID engagement.

The Copilot answer is more useful and comprehensive, but less rigorous about regulatory status and sourcing. It overgeneralizes FDA’s receptiveness as “support,” does not clearly label ICH E20 and the Bayesian guidance as drafts, and conflates Project Optimus with formal guidance.

Revised verdict: Copilot is the stronger solution overall; Parseс is more cautious and narrowly more truthful, but materially less robust and complete.

